• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

微小 RNA 与肝细胞癌发病机制：对机制和治疗机会的深入了解。

MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities.

机构信息

Laboratory for Cancer Medicine, Harry Perkins Institute of Medical Research, QEII Medical Centre, Perth, WA 6009, Australia.

Centre for Medical Research, The University of Western Australia, Perth, WA 6009, Australia.

出版信息

Int J Mol Sci. 2024 Aug 29;25(17):9393. doi: 10.3390/ijms25179393.

DOI:10.3390/ijms25179393
PMID:39273339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11395074/
Abstract

Hepatocellular carcinoma (HCC) presents a significant global health burden, with alarming statistics revealing its rising incidence and high mortality rates. Despite advances in medical care, HCC treatment remains challenging due to late-stage diagnosis, limited effective therapeutic options, tumor heterogeneity, and drug resistance. MicroRNAs (miRNAs) have attracted substantial attention as key regulators of HCC pathogenesis. These small non-coding RNA molecules play pivotal roles in modulating gene expression, implicated in various cellular processes relevant to cancer development. Understanding the intricate network of miRNA-mediated molecular pathways in HCC is essential for unraveling the complex mechanisms underlying hepatocarcinogenesis and developing novel therapeutic approaches. This manuscript aims to provide a comprehensive review of recent experimental and clinical discoveries regarding the complex role of miRNAs in influencing the key hallmarks of HCC, as well as their promising clinical utility as potential therapeutic targets.

摘要

肝细胞癌 (HCC) 对全球健康构成重大负担，其发病率上升和死亡率高的惊人统计数据令人震惊。尽管医疗保健取得了进步，但由于 HCC 的晚期诊断、有限的有效治疗选择、肿瘤异质性和药物耐药性，其治疗仍然具有挑战性。MicroRNAs (miRNAs) 作为 HCC 发病机制的关键调节因子引起了广泛关注。这些小的非编码 RNA 分子在调节基因表达方面发挥着关键作用，参与了与癌症发展相关的各种细胞过程。了解 HCC 中 miRNA 介导的分子途径的复杂网络对于揭示肝癌发生的复杂机制以及开发新的治疗方法至关重要。本文旨在全面综述 miRNA 在影响 HCC 关键特征方面的复杂作用的最新实验和临床发现，以及它们作为潜在治疗靶点的有前途的临床应用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/38af917ee274/ijms-25-09393-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/c32625994a49/ijms-25-09393-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/5a76e26eefa2/ijms-25-09393-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/f416cd3cb98c/ijms-25-09393-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/12ebd0ff1de6/ijms-25-09393-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/e875cd3648a6/ijms-25-09393-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/79c6297163cb/ijms-25-09393-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/38af917ee274/ijms-25-09393-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/c32625994a49/ijms-25-09393-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/5a76e26eefa2/ijms-25-09393-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/f416cd3cb98c/ijms-25-09393-g003a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/12ebd0ff1de6/ijms-25-09393-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/e875cd3648a6/ijms-25-09393-g005a.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/79c6297163cb/ijms-25-09393-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/519c/11395074/38af917ee274/ijms-25-09393-g007.jpg

相似文献

1
MicroRNAs in Hepatocellular Carcinoma Pathogenesis: Insights into Mechanisms and Therapeutic Opportunities.微小 RNA 与肝细胞癌发病机制：对机制和治疗机会的深入了解。
Int J Mol Sci. 2024 Aug 29;25(17):9393. doi: 10.3390/ijms25179393.
2
Deciphering the Molecular Complexity of Hepatocellular Carcinoma: Unveiling Novel Biomarkers and Therapeutic Targets Through Advanced Bioinformatics Analysis.解析肝细胞癌的分子复杂性：通过先进的生物信息学分析揭示新的生物标志物和治疗靶点。
Cancer Rep (Hoboken). 2024 Aug;7(8):e2152. doi: 10.1002/cnr2.2152.
3
The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment.微小RNA在肝细胞癌中的作用：从分子生物学到治疗
Molecules. 2014 May 19;19(5):6393-406. doi: 10.3390/molecules19056393.
4
Cancer-related microRNAs and their role as tumor suppressors and oncogenes in hepatocellular carcinoma.癌症相关 microRNAs 及其作为肝癌抑癌基因和癌基因的作用。
Histol Histopathol. 2013 Apr;28(4):437-51. doi: 10.14670/HH-28.437. Epub 2012 Dec 7.
5
Involvement of microRNAs and their potential diagnostic, therapeutic, and prognostic role in hepatocellular carcinoma.微小 RNA 的参与及其在肝细胞癌中的潜在诊断、治疗和预后作用。
J Clin Lab Anal. 2022 Oct;36(10):e24673. doi: 10.1002/jcla.24673. Epub 2022 Aug 29.
6
Hepatitis B virus and microRNAs: Complex interactions affecting hepatitis B virus replication and hepatitis B virus-associated diseases.乙型肝炎病毒与微小RNA：影响乙型肝炎病毒复制及乙型肝炎相关疾病的复杂相互作用
World J Gastroenterol. 2015 Jun 28;21(24):7375-99. doi: 10.3748/wjg.v21.i24.7375.
7
Molecular and Functional Roles of MicroRNAs in the Progression of Hepatocellular Carcinoma-A Review.微小 RNA 在肝细胞癌进展中的分子和功能作用——综述。
Int J Mol Sci. 2020 Nov 7;21(21):8362. doi: 10.3390/ijms21218362.
8
Role of epigenetic aberrations in the development and progression of human hepatocellular carcinoma.表观遗传异常在人类肝细胞癌发生发展中的作用。
Cancer Lett. 2014 Jan 28;342(2):223-30. doi: 10.1016/j.canlet.2012.01.038. Epub 2012 Feb 2.
9
Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison.用于肝细胞癌诊断、预后和治疗的生物标志物 microRNAs：功能调查与比较。
Sci Rep. 2016 Dec 5;6:38311. doi: 10.1038/srep38311.
10
MicroRNA-342-3p is a potent tumour suppressor in hepatocellular carcinoma.微小RNA-342-3p是肝细胞癌中一种有效的肿瘤抑制因子。
J Hepatol. 2021 Jan;74(1):122-134. doi: 10.1016/j.jhep.2020.07.039. Epub 2020 Jul 30.

引用本文的文献

1
Epi-nutrients for cancer prevention: Molecular mechanisms and emerging insights.用于癌症预防的表型营养素：分子机制与新见解
Cell Biol Toxicol. 2025 Jul 15;41(1):116. doi: 10.1007/s10565-025-10054-2.
2
MiR-133a-5p Facilitates Cuproptosis in Hepatocellular Carcinoma Through Targeting of ATP7B.MiR-133a-5p通过靶向ATP7B促进肝细胞癌中的铜死亡。
J Inflamm Res. 2025 May 22;18:6607-6622. doi: 10.2147/JIR.S515647. eCollection 2025.
3
The SOX gene superfamily in oncogenesis: unraveling links to ncRNAs, key pathways, chemoresistance, and gene editing approaches.

本文引用的文献

1
Etiologically Significant microRNAs in Hepatitis B Virus-Induced Hepatocellular Carcinoma.乙型肝炎病毒诱导的肝细胞癌中的有意义的 microRNAs。
OMICS. 2024 Jun;28(6):280-290. doi: 10.1089/omi.2024.0071. Epub 2024 May 31.
2
The Role of microRNAs in Hepatocellular Cancer: A Narrative Review Focused on Tumor Microenvironment and Drug Resistance.微小 RNA 在肝细胞癌中的作用：聚焦肿瘤微环境和耐药性的叙述性综述。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241239188. doi: 10.1177/15330338241239188.
3
Growth signaling autonomy in circulating tumor cells aids metastatic seeding.
SOX基因超家族在肿瘤发生中的作用：揭示与非编码RNA、关键信号通路、化疗耐药性及基因编辑方法的联系
Naunyn Schmiedebergs Arch Pharmacol. 2025 May 20. doi: 10.1007/s00210-025-04229-1.
4
Interplay between NETosis and the lncRNA-microRNA regulatory axis in the immunopathogenesis of cancer.中性粒细胞胞外陷阱形成（NETosis）与lncRNA-微小RNA调控轴在癌症免疫发病机制中的相互作用
J Physiol Biochem. 2025 May 13. doi: 10.1007/s13105-025-01082-x.
5
Circulating miR-485-5p as a potential diagnostic and prognostic biomarker for HCV-related hepatocellular carcinoma.循环miR-485-5p作为丙型肝炎病毒相关肝细胞癌的潜在诊断和预后生物标志物。
Clin Exp Med. 2025 Apr 10;25(1):110. doi: 10.1007/s10238-025-01625-y.
6
RNAa: Mechanisms, therapeutic potential, and clinical progress.RNA激活：作用机制、治疗潜力及临床进展。
Mol Ther Nucleic Acids. 2025 Feb 21;36(2):102494. doi: 10.1016/j.omtn.2025.102494. eCollection 2025 Jun 10.
7
Independent prognostic significance of tissue and circulating microrna biomarkers in hepatocellular carcinoma.组织和循环微RNA生物标志物在肝细胞癌中的独立预后意义
Discov Oncol. 2025 Mar 8;16(1):281. doi: 10.1007/s12672-025-02043-y.
8
Transcriptomic-Based Identification of miR-125a Novel Targets in Human Hepatocarcinoma Cells.基于转录组学鉴定人肝癌细胞中miR-125a的新靶点
Biomolecules. 2025 Jan 18;15(1):144. doi: 10.3390/biom15010144.
循环肿瘤细胞中的生长信号自主性有助于转移播种。
PNAS Nexus. 2024 Jan 25;3(2):pgae014. doi: 10.1093/pnasnexus/pgae014. eCollection 2024 Feb.
4
Suppression of hepatocellular carcinoma progression by long noncoding RNA apolipoprotein C1 pseudogene via the regulation of the microRNA-106b-PTEN axis.长链非编码RNA载脂蛋白C1假基因通过调控微小RNA-106b-PTEN轴抑制肝细胞癌进展
Transl Cancer Res. 2023 Dec 31;12(12):3752-3763. doi: 10.21037/tcr-23-2189. Epub 2023 Dec 26.
5
MicroRNA-204-5p Inhibits Hepatocellular Carcinoma by Targeting the Regulator of G Protein Signaling 20.微小RNA-204-5p通过靶向G蛋白信号调节因子20抑制肝细胞癌
ACS Pharmacol Transl Sci. 2023 Nov 6;6(12):1817-1828. doi: 10.1021/acsptsci.3c00114. eCollection 2023 Dec 8.
6
miR-612 Enhances RSL3-Induced Ferroptosis of Hepatocellular Carcinoma Cells via Mevalonate Pathway.miR-612通过甲羟戊酸途径增强RSL3诱导的肝癌细胞铁死亡
J Hepatocell Carcinoma. 2023 Dec 6;10:2173-2185. doi: 10.2147/JHC.S433332. eCollection 2023.
7
CRISPR/Cas9 screens unravel miR-3689a-3p regulating sorafenib resistance in hepatocellular carcinoma via suppressing CCS/SOD1-dependent mitochondrial oxidative stress.CRISPR/Cas9 筛选揭示 miR-3689a-3p 通过抑制 CCS/SOD1 依赖性线粒体氧化应激调节肝癌索拉非尼耐药。
Drug Resist Updat. 2023 Nov;71:101015. doi: 10.1016/j.drup.2023.101015. Epub 2023 Oct 29.
8
Hypoxia-induced exosomes facilitate lung pre-metastatic niche formation in hepatocellular carcinoma through the miR-4508-RFX1-IL17A-p38 MAPK-NF-κB pathway.缺氧诱导的外泌体通过 miR-4508-RFX1-IL17A-p38 MAPK-NF-κB 通路促进肝癌肺转移前微环境的形成。
Int J Biol Sci. 2023 Sep 4;19(15):4744-4762. doi: 10.7150/ijbs.86767. eCollection 2023.
9
cDCBLD2 mediates sorafenib resistance in hepatocellular carcinoma by sponging miR-345-5p binding to the TOP2A coding sequence.cDCBLD2 通过海绵吸附 miR-345-5p 结合 TOP2A 编码序列介导肝癌对索拉非尼的耐药性。
Int J Biol Sci. 2023 Aug 28;19(14):4608-4626. doi: 10.7150/ijbs.86227. eCollection 2023.
10
Engineered small extracellular vesicles loaded with miR-654-5p promote ferroptosis by targeting HSPB1 to alleviate sorafenib resistance in hepatocellular carcinoma.装载miR-654-5p的工程化小细胞外囊泡通过靶向HSPB1促进铁死亡，以减轻肝细胞癌中的索拉非尼耐药性。
Cell Death Discov. 2023 Sep 30;9(1):362. doi: 10.1038/s41420-023-01660-2.